Thiazolylpenicillins and their preparation

ABSTRACT

A NEW CLASS OF PENICILLINS IS DISCLOSED, WHICH PENICILLINS CONTAIN A THIAZOLY, A THIAZOLYLMETHYL OR A SUBSTITUTED THIAAZOLYLMETHYL GROUP IN THE SIDE CHAIN. METHOD OF SYNTHESIS AND EVALUATIONS OF ANTI-BACTERIAL ACTIVITY ARE DESCRIBED.

Patented Apr. 13, 1971 United States Patent cc $574,799

1 2 t 3 574 799 6 -[z z-(b -chlclmrothiazole-)acetamido]penicillanic acid.

nzy bonylaminothiazole-4)acetamido] THIAZOLYLPENICIiLINSAND THEIR e PREPARATION pemcrllamc ac1d.

Peter Bamberg Enhorna and Berndt Olof Harald S'ob r 6'[0"gzplienyl'4'methylthiazole5)acetamido1Penicil Sodertalje, weden, gissignor to AkfiebolagetlAsirg: lanic acid, 6-[a-(2-chloro-4-methylthiazole-5)acetsodertaljel, Sweqen amido1penicillanic acid, 6-[a-(2-chloro-4-phenyl-5) Np Drqwlpg Flleq Mar. 1 19 Ser. 714,000 acetamrdo1penicillanic acid, 6-[04-(2,4-diphenylthiazole- Clalms riorit a lication Great Britain, Mar. 20, 1967, 5 )-acetamidolpenicillanic p v Int l2,%%07{l6g9/16 phenylthiazole-S):acetamido]penicillanic acid, 6-[a-(2- US. Cl. 260 4391 7 Claims 10 (6)-tolyl-4-phenylth1azole-5)acetamido1penicillanic acid,

1 z- 2mg-tolyl-4-phenylth1azo1e-5 acetamido] pemcllanic ac1 ABSTRACT OF THE DISCLOSURE The invention also comprises non-toxic salts of com- A new class of penicillins is disclosed, which penicillins palms? of the Fan-Hula Salts lI-lcl'ude non'tm-dc contaln a thiazolyl, a thiazolylmethyl or a substituted {meta 1c Salts as potassmm cal-clum and ahlqnnthiaaolylmethyl group in the side chain. Method of syni Salts ammomum Salts i sl-lbstltutedamnion-111m thesis and evaluations of anti-bacterial activity are dea salt-s of Sud-1 nontoxic umms-as malkylammes Scnbed. including triethylamlne, procaine, dibenzylamine, N- benzyl-B-phenethylamme, l-ephenamine, N,N-dibenzylethylenediamine, dihydroabieth lamine, N,N-bisdeh dro- T p Q mventlqn relatesfo flllazolylpenlQllllns and abietylethylenediamine, and oi her amines which have "P P q ly, It concerns PeniCllliHs been used to form salts with benzylpenicillih or phenoxytaming thlaozlyl, a thlazolylmethyl or a substituted thiamathylpenicinin.

Zolylmethyl group 111 the slde chaln- The Compounds P The present invention further provides a process for the pared according to the present invention are of value as 2 preparation of compounds of the general Formula I, which antibacterial agents, as nutritional supplements in animal process comprises mi a compound of h n l feeds as agents for treatment of mastitis in cattle and as f l therapeutic agents in poultry and animals, including man RCOX 1n the treatment of infectious dlseases caused by micro- 1.1) organism- Accordingly the present invention provides Compounds 'wlth 6-arn1nopen1c1l1an1c acid or a salt of it in organic or f the general f l aqueous organic solutlons or with a derivative of fi-aminopenicillanic acid of the general formula Y S I 3 R CO NH ?H CH 0 CH3 5 Y NH CH I(H xlc (I) CON-CHCOOR' (III) wheremkis thiazolyl or the group in organic solutions, where R has the same meaning as R IH 40 above, R represents trialkylsilyl, a phenacyl group which may be unsubstituted or substituted with one or more halogen atoms, lower alkyl, lower alkoxy or nitro groups or where R is hydrogen, lower alkyl, lower alkenyl, lower R represents alkinyl or monocarbocyclic aryl containing 6 to 10 carv bon atoms and R is a thiazolyl group which is unsubstituted or substituted with at least one member of the class consisting of lower alkyl, monocarbocyclic aryl of R 6 to 10 carbons, monocarbocyclic heterocycle, aralkyl of at most 10 carbon atoms, halogen, hydroxy, lower alkoxy, monocarbocyclic aryloxy of 6 to 10 carbon atoms, lower alkanoyloxy, monocarbocyclic aroyloxy of 6 to 10 carbon atoms, amino and amino substituted with lower alkyl, monocarbocyclic aryl of 6 to 10 carbon atoms or aralkyloxycarbonyl of at most 10 carbon atoms, the term lower meaning containing up to -6 carbon atoms, and R when bound in position 4 being substituted with substituents 55 others than lower alkyl.

Illustrative examples of compounds according to the wherein R R and R may be the same or diiferent and each represents a monovalent hydrocarbon group, for example an alkyl, aryl or aralkyl group; CO-X and YNH are groups of atoms capable of reacting with each other with formation of a carbon-nitrogen bond, so that, if necessary or desired after hydrolysis, a -CONH-group is obtained. Particularly Y is hydrogen or at the same time as R is a trialkylsilyl group.

The compound of the general Formula II may be an acid chloride or its functional equivalent such as an acid azide, an acid bromide, an activated ester, an anhydride, a mixed mventlon anhydride, especially one formed with an alkoxy formic 6-(4-thiazolylcarboxamido)Penicillanic acidacid or a derivative obtained by reaction between a car- )acetamido]penicillanic acidboxylic acid and a carbodiimide or other compounds func- 6-[a-(4-methY1thiaZ01e-5)acetamidolpenicillaflic acid, tioning in the same way, such as N,N'-carbonyldiimid- 6-[a-(4-methY1thiaZ01e-2)acetamidolpenicillanic acidazole, N-ethyl-5-phenylisoxazolium-3'-sulphouate or N- 6-[a-(4-PheI1Y1thiaZ01e-5)acetamidolpeflicillanic d tert.-butyl-S-methylisoxazolium perchlorate.

6[a-(2-pheuylthiazole-5 )acetamido1penicillanic acid, The reaction is desirably carried out in an organic '6-[w-(2-0-t01Y1thiaZ01e-4)acetamidolpenicillanic acid, solvent such as tetrahydrofuran, dimethylformamide, ace- 6-[ -oly l ]p ni i l ic acid, tonitrile or mixtures thereof, and at room temperature 6-[a-(2-m-tolylthiazole-5)acetamido1penicillanic acid, 01* below, preferably between -5 and +5 C. In order 6-[a-(2-o-chlorophenylthiazole-S )acetamido1penicilto obtain complete acylation of the 6-aminopenicil1anic lanic acid. esters (III) an excess of the acylating agent may be used 6-[oz-(2-B-pyridylthiazole-4)acetamido1penicillanic acid. and the acylation product can be freed from excess of 6-[a-(2-chlorothiazo1e-4) acetamido1penicillanic acid, acylating agent by treatment at pH 7 with water. After purification of the acylation product the ester linkage may readily be cleaved by simple procedures without any appreciable destruction of the penicillin molecule taking place. Cleavage can be brought about by treatment with certain basic or nucleophilic agents in aqueous or nonaqueous solution. In non-aqueous media the penicillin may be obtained directly in crystalline form e.g. as the sodium or potassium salt. The ester group can also be removed by treatment with acid under mild conditions.

Certain of the penicillins defined in Formula I with R =H may be prepared by fermentation or enzymatic coupling. If the compounds of the general Formula II contain one or more asymmetric centres the resulting compounds of the general Formula I may exist in different diastereoisomeric forms, which all are biologically active. It is to be understood that the present invention comprises the diastereoisomers as well as mixtures of them.

The following examples illustrate the invention:

EXAMPLE 1 6 [a- (4-methylthiazole-5) acetamido] penicillanic acid To a stirred ice cold mixture of 4-methyl-thiazole-5- acetic acid (1.2 g.) and tributyltin-6-aminopenicillinate (2.65 g.) in tetrahydrofuran (10 ml.) was added N,N'- dicyclohexylcarbodiimide (1.1 g.) in tetrahydrofuran ml.). After stirring at 4 C. for 15-20 hours ethyl acetate (50 ml.) was added. The dicyclohexylurea (about 1.1 g.) was removed by filtration, water (30 ml.) was added and the pH adjusted to 6.8. The aqueous layer was discarded and the organic phase was dried and the solvent removed in vacuo to yield an oily residue (2.95 g.) which was dissolved in dimethylformarnide (3 ml.) and treated With potassium thiophenolate (0.69 g.) in dimethylformamide (2 ml.) for 30 min. at 25 C. Ether (100-150 ml.) was added and the precipitated potassium salt of 4-thiazolylmethylpenicillin was collected by filtration. Purity 70%, IR-absorption 1760 cmf Minimum inhibitory concentration (MIC) against Staphylococcus aureus, Oxford 0.13 mcg./ml. and against Streptococcus pyogenes 0.01 meg/ml.

In a similar way the following penicillins were prepared starting with the corresponding thiazolylacetic acids:

6-[a-(thiazole-S)acetamido]penicillanic acid, purity 77%, IR-absorption: 1765 cm.- MIC against Staph. aureus, Oxford 0.13 meg/ml., against Streptoc. pyogenes 0.01 meg/ml. and against E. coli 625 mcg./ml.

6 [a-(2-phenyl-4-methylthiazole-)acetamido]penicillanic acid, purity 91%, IR-absorption at 17 60 crnf MIC against Staph. aareus, Oxford 0.03 meg/ml. and against Streptoc. pyogenes 0.006 mcg./ml.

6-[a-(2-o-chlorophenyl 4 methylthiazole-S)acetamido] penicillanic acid, purity 92%, IR-absorption at 1760 cmf MIC against Staph. aureus, Oxford 0.03 mcg./ ml. and against Streptoc. pyogenes 50.006 meg/ml.

6-[a-(2 chlorothiazole 4)acetamido]penicillanic acid, purity 99%, IR-absorption at 1755 cm. MIC against Staph. aureus, Oxford 0.03 mcg./ml. and against Strcptoc. pyogenes 50.006 meg/ml.

6-[a-(2 o-tolylthiazole 4)acetamido]penicillanic acid, purity 100%, IR-absorption 1765 cm. MIC against Staph. aureus, Oxford 0.06 meg/ml. and against Streptoc. pyogenes 50.006 mcg./ml.

6-[a-( 2 m-tolylthiazole 4)acetamido]penicillanic acid, purity 93.5%, IR-absorption 1765 cmf MIC against Staph. aareas, Oxford 0.06 meg/ml. and against Streptoc. pyogenes 0.01 mcg./ml.

6-[a-(2 p tolylthiazole-4)acetamidoJpenicillanic acid, purity 100%, IR-absorption 1755 cmr MIC against Staph. aureus, Oxford 0.06 mcg./ ml. and against Streptoc. pyogcnes 0.01 mcg./ml.

6-[a-(2-o-chlorophenylthiazole 4)acetamido]penicillanic acid, purity 89%, IR-absorption 1760 cmr' MIC against Staph. aureus, Oxford 0.03 mcg./ml. and against Streptoc. pyogenes 50.006 meg/ml.

G-[a-(Z m-chlorophenylthiazole 4)acetamido]penicillanic acid, purity 81%, IR-absorption 1760 cmr MIC against Staph. aureus, Oxford 0.03 mcg./ml. and against Streptoc. pyogenes 50.006 meg/ml.

6-[a-(2-p-chlorophenylthiazole 4) acetamido]penicillanic acid, purity 76%, IR-absorption 1760 cmr MIC against Staph. aureus, Oxford 0.06 mcg./n1l. and against Streptoc. pyogenes 50.006 meg/ml.

6-[u-(4 methylthiazole 2)acetamido]penicillanic acid, purity 92%, IR-absorption 17 60 cm.- MIC against Staph. aureus, Oxford 0.06 mcg./ml. and against Streptoc. pyogenes 0.01 mcg./ml.

6-[a-(2-benzyloxycarbonylaminothiazole 4)acetamido] penicillanic acid, purity 74%, IR-absorption 1750 cmr MIC against Staph. aureus, Oxford 0.13 meg/ml. and against Streptoc. pyogenes 0.01 mcg./ml.

6-[a-(2-benzoyloxycarbonylamino 4 phenylthiazole-S) acetamido]penicillanic acid, purity 59%, IR-absorption 1745 cm.- MIC against Staph. aureus, Oxford 0.03 mcg./ml. and against Streptoc. pyogenes 0.01 meg/ml.

6 [a-(2-fi-pyridylthiazole-4)acetamido]penicillanic acid,

purity IR-absorption 1760 cm.

EXAMPLE 2 6-[a-(4-phenylthiazole-5 acetamidoJpenicillanic acid To a stirred ice cooled mixture of p-bromophenacyl-6- aminopenicillanate benzenesulponic acid salt (5.71 g., 0.01 mole) and 4 pl1enylthiazole-5-acetic acid (2.63 g., 0.012 mole) in dimethylformamide (25 ml.) N,N-dicyclohexylcarbodiimide (2.26 g., 0.011 mole) in dimethylformamide (10 ml.) was added dropwise. After 15 hours at +4 C. the mixture was poured into ice water and ethyl acetate and filtered, the water phase was extracted once more with ethyl acetate, the combined organic phases were washed with 2 N sodium bicarbonate and brine, dried and evaporated. The oily residue (7.8 g.) was dissolved in dimethylforrnamide (15 ml.) and potassium thiophenoxide (1.48 g., 0. 01 mole) was added. After 30 min. at 20-25 C. the solution was poured into 200 ml. of acetone/ether 1:1. The precipitated product was collected by filtration. IR-absorption at 1765 cm.- (fl-lactam C=O), purity 95%, minimum inhibitory concentration (MIC) against Staph. aureus, Oxford 0.03 meg/ml., and against Streptoc. pyogenes 0.006 mcg./ ml.

EXAMPLE 3 6- [a- (2-phenylthiazole-4) acetamido1penicillanic acid To a stirred mixture of triethylamine (1.4 ml., 0.01 mole) and 2-phenylthiazole-4-acetic acid (2.19 g., 0.01 mole) in tetrahydrofuran (50 ml.) kept at l0 'C. isobutylchloroformate (1.37 g., 0.01 mole) in ether (5 ml.) was added dropwise. After 10 min. this mixture was added to a stirred suspension of 6-aminopenicillanic acid (2.16 g., 0.01 mole) and triethylamine (4.2 ml., 0.03 mole) in methylene chloride at 0 C. The mixture was stirred for 2 hours while the temperature was allowed to rise to 23 C., and then poured into ice water. The pH was adjusted to 2.5 and the product extracted with ethyl acetate. After drying the organic phase the penicillin was precipitated as its potassium salt by addition of potassium 2-ethylhexanoate. IR-absorption at 1760 cm? (,8- lactam C=O), purity 98%, MIC against Staph. aurcus, Oxford 0.03 mcg./ml. and against Streptoc. pyogenes 50.006 meg/ml.

EXAMPLE 4 6- (4-thiazolylcarboxamido penicillanic acid To an ice cooled stirred solution of tributyltin 6-aminopenicillinate (21.1 g., 0.042 mole) and triethylamine (15.5 ml., 0.11 mole) in dimethylformamido (200 ml.) thiazolyl-4-carbonylchloride hydrochloride (9.2 g., 0.05 mole) in dimethylformamide (100 ml.) was added dropwise. After 15 hours at +4 C. ethyl acetate (400 ml.) was added and the mixture was filtered. The filtrate was poured into 600 ml. of ice water and the pH adjusted to 6.5. The organic layer was washed with water, dried and evaporated in vacuo. The residue was dissolved in dimethylformamide (30 ml.) and charcoaled. Then potassium thiophenoxide (5 g., 0.034 mole) was .added After 30 min. the solution was poured into acetone (250 ml.) and the product collected by filtration. IR-absorption at 1760 cm. (B-lactam C-=O), purity 68%, MIC against Staph. aureus, Oxford 1.25 mcg./ml.

What we claim is:

1. A compound selected from the group consisting of those having the formula CH3 R0H2C0NHoH-0fi o cm 01 I---c11c0o11 wherein R is selected from the group consisting of wherein R is hydrogen, lower alkyl or halogen; wherein R is hydrogen, lower alkyl or phenyl; and therapeutically acceptable, non-toxic salts thereof.

2. A compound selected from the group consisting of -6-[a-(2-chlorothiaZole-4)acetamido] penicillanic acid and a therapeutically acceptable, non-toxic salt thereof.

3. A compound selected from the group consisting of 6-[a-(2-phenylthiazole-4)acetamidoJpenicillanic acid and a therapeutically acceptable, non-toxic salt thereof.

4. A compound selected from the group consisting of 6-[a-(thiaZole-5)acetamido1penicillanic acid and a therapeutically acceptable, non-toxic salt thereof.

5. A compound selected from the group consisting of 6-[a-(4-phenylthiazole-5 acetamido] penicillanic acid and a therapeutically acceptable, non-toxic salt thereof.

6. A compound selected from the group consisting of 6-[u (2 phenyl-4-methylthiazole-5)acetamido1penicillanic acid and a therapeutically acceptable, non-toxic salt thereof.

7. A compound selected from the group consisting of 6-[oc (2-0-chlorophenyl-4-methylthiazole 5)acetamido] penicillanic acid and a therapeutically acceptable, nontoxic salt thereof.

References Cited UNITED STATES PATENTS 3,271,407 9/1966 Raap et a1. 260-2391 3,296,250 1/1967 Fraser 260-2391 NICHOLAS S. RIZZO, Primary Examiner U.S. Cl. X.R. 260-999 g 2 g UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3 57 799 Dated April 3 1971 PETER BAMBERG et a1 Inventor(s) it is certified that: error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Col. 1, line 47, "carbons" should be carbon atoms Col 2, line 8, hlorophenyll" should be chlorophenyl-M- Col. 2, lines &5 and 16 reads:

-Sn-R flould read:

R -sn -R 6 Col. 3, line 22, reads "6[ should read 6[ Col. line 29 reads "benzenesulponic" should read benzenesulphonic C01 5 line 3 4 reads "N-C-CH should read N-C-CH3 Signed and sealed this 7th day of September 1971 (SEAL) Attest:

EDWARD M.FLETCHER,JR. ROBERT GOTTSCHALK 

